Introduction
============

Alveolar soft part sarcoma is a morphologically and clinically distinct neoplasm, that was first termed and defined by Christopherson *et al* ([@b1-ol-0-0-5696]), in 1952. The name 'alveolar' was derived from its pseudo alveolar appearance, with clustered polygonal cells with eosinophilic cytoplasm ([@b1-ol-0-0-5696]). Although the tissue origin of alveolar soft part sarcoma still remains unclear, molecular studies have revealed chromosomal rearrangements at translocation (X;17)(p11;q25), resulting in an alveolar soft part sarcoma critical region 1 (*ASPSCR1*) and transcription factor E3 (*TFE3*) gene fusion ([@b2-ol-0-0-5696]--[@b4-ol-0-0-5696]). The alveolar soft part sarcoma tumor usually presents as a painless, slow growing mass without functional impairment ([@b1-ol-0-0-5696]). Typically, there is a lack of symptoms, and it is easily overlooked, with metastasis to the lung or brain often the first signs of manifestation of the disease ([@b5-ol-0-0-5696]--[@b12-ol-0-0-5696]). Prognosis is poor despite the slow growth of the tumor ([@b5-ol-0-0-5696]--[@b12-ol-0-0-5696]). There has been partial initial success with tyrosine kinase inhibitors ([@b13-ol-0-0-5696]--[@b15-ol-0-0-5696]), however, active systemic therapy has not been successful for the majority of patients with metastatic diseases ([@b9-ol-0-0-5696],[@b15-ol-0-0-5696],[@b16-ol-0-0-5696]). This emphasizes the requirement for alternative treatments such as immunotherapy.

Cases with spontaneous regression of alveolar soft part sarcoma have previously been reported ([@b17-ol-0-0-5696]--[@b19-ol-0-0-5696]). However, the mechanisms underlying the spontaneous regression of this type of tumor remain uncertain, and the local immune reaction is considered to be a possible causative factor ([@b20-ol-0-0-5696]).

Previous studies have demonstrated efficacy of immunotherapeutic strategies against cancer, where antitumor cytotoxic T lymphocytes are induced by cancer vaccination ([@b21-ol-0-0-5696]--[@b24-ol-0-0-5696]). Antitumor responses are modulated by the recognition of immunogenic epitopes in the context of human leukocyte antigen (HLA) class I in the tumors ([@b21-ol-0-0-5696]). Therefore, it is important to evaluate the infiltrations of immune cells and the presence of HLA class I in the tumors. Using immunohistochemistry, the present study evaluated the expression profiles of HLA class I and the presence of intratumoral immune cells in alveolar soft-part sarcoma.

Materials and methods
=====================

### Patients

The present study was approved by the Institutional Review Boards of the Niigata University Hospital (Niigata, Japan) and Niigata Cancer Hospital (Niigata, Japan), and complies with the Declaration of Helsinki. Written informed consent was obtained from all patients and/or their families prior to enrollment in the present study. Between January, 1985 and December, 2014, 10 patients with alveolar soft part sarcoma were treated at the Niigata University Hospital and Niigata Cancer Hospital. Data from these patients were reviewed retrospectively. The demographic data for the patients are summarized in [Table I](#tI-ol-0-0-5696){ref-type="table"}. The average age at the time of primary treatment was 32 years (range, 12--75 years). The patient group was comprised of six females and four males. The tumor diameter ranged between 30 and 200 mm (average 103 mm).

### Immunohistochemistry

The surgically excised tumor samples were routinely fixed in 10% buffered formalin for 18--20 h at room temperature, prior to being embedded in paraffin. A single representative section of each sample (4 µm thick) was cut and attached to amino silane (APS) coated glass slides (SFRC11; Matsunami Glass Ind., Ltd., Osaka, Japan.). Hematoxylin (Vector Laboratories, Inc. Burlingame, CA, USA) and eosin was used for routine staining. The tissue sections were deparaffinized in xylene and rehydrated in graded ethanol. The slides were steamed for antigen retrieval in 10 mM citrate buffer at pH 6.0 (Dako North America, Inc., Carpinteria, CA, USA) at 85--100°C for 40 min. Parts of each sample were treated with 0.2% trypsin solution at 37°C for 20 min, for antigen retrieval. Following cooling for 15 min, the slides were immersed in methanol with 0.3% hydrogen peroxide for 20 min at room temperature, in order to block the endogenous peroxidase activity. Subsequently, the slides were incubated with PBS supplemented with 10% goat serum (Dako North America, Inc.) for 20 min at room temperature, to reduce the occurrence of nonspecific reactions. The slides were then incubated with the primary antibodies at 4°C overnight, followed by incubation with a universal immunoperoxidase polymer, including anti-mouse and anti-rabbit antibodies (Histofine Simple Stain MAX PO \[MULTI\]; dilution 1:1; cat. no. 424141, Nichirei Biosciences, Inc., Tokyo, Japan) for 30 min at room temperature. The peroxidase activity was detected with 3′-diaminobenzidine tetrahydrochloride (Nichirei). The slides were counterstained with hematoxylin. The following primary antibodies were used: Anti-CD3 (rabbit monoclonal antibody; clone: SP7; dilution 1:1; cat. no. 713591; Nichirei), anti-CD4 (mouse monoclonal antibody; clone:1F6; dilution 1:1; cat. no. 713181; Nichirei), anti-CD8 (mouse monoclonal antibody; clone: C8/144B; dilution 1:1; cat. no. 713201; Nichirei) anti-CD56 (monoclonal mouse anti-human CD56; clone: 1B6; dilution 1:1; cat. no. 713331; Nichirei), anti-CD20 (mouse monoclonal antibody; clone: L26; dilution 1:1,000; cat. no. SL26; Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan), anti-CD45 (monoclonal mouse anti-human antibody; clone: 2B11; dilution 1:200, cat. no. 2B11; Kyowa Hakko Kirin) anti-CD68 (monoclonal mouse anti-human antibody; clone: KP1; dilution 1:5,000; cat. no. Nr.M0814; Dako North America, Inc.) anti-CD138 (monoclonal mouse anti-human CD138; clone: MI15; dilution 1:50; cat. no. Nr.M722; Dako North America, Inc.), anti-CD163 (monoclonal mouse anti-human antibody; clone: 10D6; dilution 1:500; cat. no. NCL-CD163; Leica Microsystems, Inc., Buffalo Grove, IL, USA) and anti HLA class I (mouse monoclonal antibody; clone: EMR8-5; dilution 1:100; cat. no. AB-46; Hokudo Co., Ltd., Sapporo, Japan).

A total of 10 fields of view from each section were assessed by two researchers by light microscopy, and cells were counted manually. The immunohistochemical results were evaluated by semi-quantitative scoring, according to a previous report ([@b23-ol-0-0-5696]) as follows: +++, high density of positive cells in the fields; ++, moderate density and +, low density.

Result
======

### Clinical course of the patients

At initial presentation, 7/10 patients had metastatic disease and 3/10 patients had developed metastasis following initial treatment. A thigh tumor with eight metastatic lung-nodules at presentation was identified in patient 10. This patient underwent wide local excision of the thigh tumor, but chemotherapy was not administered, as the patient\'s parents did not approve the additional cytotoxic treatment. For one year following excision of the primary tumor, the patient received monthly intravenous infusions containing 1×10^10^ ex vivo expanded and interferon (IFN) α-treated peripheral blood mononuclear cells at another hospital ([@b21-ol-0-0-5696]). All but one of the lung nodules slowly diminished in size in the six months following the initial surgery. Only one lung-nodule was detected by computed tomography, 24 months following surgery. The size of the lung tumor was stable, and endoscopic resection of the tumor was carried out nine years subsequent to the initial presentation. The patient was free of metastatic disease two years following the metastasectomy ([Fig. 1](#f1-ol-0-0-5696){ref-type="fig"}). In total, during the present study, seven patients succumbed to alveolar soft-part sarcoma, two patients survived with metastatic disease, and one patient survived and was free from cancer.

### Immunohistochemistry

As presented in [Figs. 2](#f2-ol-0-0-5696){ref-type="fig"}--[4](#f4-ol-0-0-5696){ref-type="fig"} almost all tumor cells of the tissue samples stained with the antibody against HLA class I. The expression of HLA class I in soft tissue tumors was examined and the level of expression differed from case to case (data not presented). Infiltration of CD3(+) T cells was demonstrated in all tumors. Scattered-moderate infiltration of CD4(+) cells was observed in 8/10 of the tumors. CD8(+) cells were revealed in all tissue samples with varying densities. Moderate infiltration of CD8(+) cells was demonstrated in tissue samples 1, 6 and 10 ([Figs. 2](#f2-ol-0-0-5696){ref-type="fig"}--[4](#f4-ol-0-0-5696){ref-type="fig"}). Intratumoral infiltration of CD10(+), CD20(+), CD56(+) or CD138(+) cells was not revealed in the tumor samples. Moderate-diffuse infiltration of CD163(+) cells was observed in all tumor samples ([Figs. 2](#f2-ol-0-0-5696){ref-type="fig"}--[4](#f4-ol-0-0-5696){ref-type="fig"}); these cells were interspersed within nests of tumor cells and the perivascular region. CD68 levels were analyzed in all tissue samples; however, precise measurements were difficult to obtain as inflammatory cells and numerous tumor cells were positive for this antigen. In case 10, the metastatic lung tumor cells were also positive for HLA class I, and moderate infiltration of CD8(+) cells was revealed in the metastatic tumor tissues ([Fig. 5](#f5-ol-0-0-5696){ref-type="fig"}; [Table II](#tII-ol-0-0-5696){ref-type="table"}).

Discussion
==========

Previous studies have demonstrated five cases of spontaneous regression of alveolar soft part sarcoma ([Table III](#tIII-ol-0-0-5696){ref-type="table"}), in which three of the five patients are Japanese ([@b17-ol-0-0-5696]--[@b19-ol-0-0-5696],[@b25-ol-0-0-5696],[@b26-ol-0-0-5696]) The high incidence of Japanese cases may due to language bias during literature review. All three Japanese patients remain alive following an extended period of remission, as determined by verbal communication with the patients. The spontaneous regression of sarcomas is rare and the actual incidence has not been reported ([@b20-ol-0-0-5696]). Although the underlying mechanism of regression is not fully known, immune mechanisms have been demonstrated in certain types of cancer ([@b20-ol-0-0-5696]).

The present study revealed moderate infiltration of CD8(+) lymphocytes in patient 10, who had long-term remission of multiple lung metastases, which suggests an anticancer immune response in this tumor. The specific immunotherapy treatment of this case is not known; however, diffuse infiltration of CD8(+) lymphocytes in the primary tumor prior to immunotherapy suggests specific immune components were activated. CD8(+) cells in malignant tumors have been associated with an improved survival rate for patients with various types of cancer, including non-small cell lung carcinoma, endometrial carcinoma, melanoma and Ewing sarcoma ([@b20-ol-0-0-5696]). In the present study, the infiltration of CD10(+), CD20(+), CD56(+) or CD138(+) cells was not identified in all tissue samples. Therefore, B or natural killer cells do not dominate the immune response in alveolar soft-part sarcoma.

The present study was designed to determine the expression levels of HLA class I and infiltration levels of immune cells in alveolar soft part sarcoma. It was revealed that the expression levels of HLA class I were preserved in all cases investigated in the current study. Previously, Tsukahara *et al* ([@b27-ol-0-0-5696]) investigated expression levels of HLA class I in bone and soft tissue tumors. Tsukahara *et al* ([@b27-ol-0-0-5696]) revealed that HLA class I was not expressed or was downregulated in 63% of bone and soft tissue tumor samples. Although the sample size in the current study is small, preservation of HLA class I expression and infiltration of CD8(+) lymphocytes in the tumor cells demonstrates noteworthy results in all cases. The results were concordant with those of previous studies, confirming the presence of an immune response in alveolar soft part sarcoma ([@b28-ol-0-0-5696]). In addition, the diffuse infiltrations of CD8(+) lymphocytes in case 10 indicates that the immune response may contribute to improved prognosis of the tumor.

Tumor-associated macrophages are stromal cells that are known to promote tumor invasion, metastasis and angiogenesis in numerous types of cancer ([@b27-ol-0-0-5696]). The macrophages are able to produce and secrete growth factors, cytokines and other inflammatory mediators that may have important roles in tumor progression ([@b29-ol-0-0-5696]). These tumor-activating functions are consistent with the results of previous clinical st9dies, demonstrating that the high macrophage density of various types of cancer is associated with a poor prognosis ([@b29-ol-0-0-5696]). In addition, a previous study also demonstrated that macrophage infiltration is associated with poor prognosis in Ewing sarcoma ([@b30-ol-0-0-5696]). However, a study of osteosarcoma revealed that macrophages were associated with a good clinical outcome ([@b31-ol-0-0-5696]). The role of macrophages in sarcoma differs depending on the tumor subtype ([@b31-ol-0-0-5696]). In the present study, CD163 macrophages infiltrated diffusely in all alveolar soft tissue tumor samples, similar to a previous study ([@b28-ol-0-0-5696]). The prognostic value of macrophages in alveolar soft part sarcoma remains controversial. Additional studies are required to improve understanding of the role of macrophages in soft tissue tumors.

In conclusion, to the best of our knowledge, the present study represents the first report of intratumoral immune cell presence in alveolar soft part sarcoma. Frequent expression of HLA class I was revealed in the tumor cells. CD8(+) cells were identified at varying densities and CD163(+) cells were present in alveolar soft part sarcoma. Moderate infiltration of CD8(+) cells was observed in the tumors of patients with a good prognosis, which may indicate the antitumor effect of immune cells in alveolar soft-part sarcoma.
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![Multiple lung metastases in case 10. Arrows show the regressing nodules following initial the surgery and the arrowhead shows the persistent nodule that was resected seven years later.](ol-13-04-2169-g00){#f1-ol-0-0-5696}

![Representative immunohistochemical reactions for HLA class 1, CD8, and CD163 in case 2. (A) HE staining; (B) diffusely positive tumor cells for HLA class 1; (C) scattered infiltration of CD8(+) immune cells; (D) diffuse infiltration of CD163(+) cells. HLA, human leukocyte antigen; CD, cluster of differentiation; HE, hematoxylin and eosin.](ol-13-04-2169-g01){#f2-ol-0-0-5696}

![Representative immunohistochemical reactions for HLA class 1, CD8 and CD163 in case 6 (A) HE staining; (B) diffusely positive tumor cells for HLA class 1; (C) moderate infiltration of CD8(+) immune cells; (D) diffuse infiltration of CD163(+) cells. HLA, human leukocyte antigen; CD, cluster of differentiation. HE, hematoxylin and eosin.](ol-13-04-2169-g02){#f3-ol-0-0-5696}

![Representative immunohistochemical reactions for HLA class 1, CD8 and CD163 in Case 10. (A) HE; (B) diffusely positive tumor cells for HLA class 1; (C) moderate infiltration of CD8(+) immune cells; (D) diffuse infiltration of CD163(+) cells. HLA, human leukocyte antigen; CD, cluster of differentiation. HE, hematoxylin and eosin.](ol-13-04-2169-g03){#f4-ol-0-0-5696}

![Representative immunohistochemical reactions for HLA class 1 and CD8 (A) diffusely positive tumor cells for HLA class 1; (B) moderate infiltration of CD8(+) immune cells. HLA, human leukocyte antigen; CD, cluster of differentiation. HE, hematoxylin and eosin.](ol-13-04-2169-g04){#f5-ol-0-0-5696}

###### 

Clinical characteristics of 10 cases with alveolar soft-part sarcoma.

  Patient   Age (years)   Gender   Site              Maximum diameter (mm)   Metastasis at presentation   Prognosis   Survival (months)
  --------- ------------- -------- ----------------- ----------------------- ---------------------------- ----------- -------------------
    1       28            M        Leg                 70                    Yes                          SOD         124
    2       61            M        Thigh               80                    Yes                          SOD         120
    3       21            F        Buttock           200                     Yes                          SOD           12
    4       25            F        Retroperitoneum   100                     No                           SOD           66
    5       75            F        Foot                70                    No                           SOD           42
    6       24            F        Axilla            120                     Yes                          SOD           10
    7       14            M        Leg                 30                    Yes                          AWD           61
    8       21            F        Retroperitoneum   150                     No                           SOD           19
    9       36            F        Thigh             160                     Yes                          AWD           16
  10        12            M        Thigh               55                    Yes                          NED         138

M, male; F, female; SOD, succumbed to disease; AWD, alive with disease; NED, no evidence of disease.

###### 

Results of immunohistochemically analysis of 10 cases of alveolar soft part sarcoma.

  Patient   HLA class I   CD3   CD4   CD8   CD10   CD20   CD45   CD56   CD138   CD163
  --------- ------------- ----- ----- ----- ------ ------ ------ ------ ------- -------
    1       +++           ++    −     ++    −      −      ++     −      −       +++
    2       +++           \+      +   \+    −      −      \+     −      −       +++
    3       +++           \+    −     \+    −      −      \+     −      −       ++
    4       +++           \+    −     \+    −      −      \+     −      −       +++
    5       +++           \+    −     \+    −      −      \+     −      −       ++
    6       +++           ++    \+    ++    −      −      ++     −      −       +++
    7       +++           \+    \+    \+    −      −      \+     −      −       ++
    8       +++           \+    \+    \+    −      −      \+     −      −       +++
    9       +++           \+    \+    \+    −      −      \+     −      −       ++
  10        +++           ++    \+    ++    −      −      ++     −      −       +++

+++, high density; ++, moderate density; +, low density; -, Negative; HLA, human leukocyte antigen; CD, cluster of differentiation.

###### 

Cases of regression without cytotoxic therapy in alveolar soft part sarcoma.

  Age   Gender   Location           Tumor size   Metastasis at presentation   Preoperative treatment                                                   Surgery for the primary tumor               Postoperative course                                                                                                                                                                                                                                                                                         Outcome                                                        Reference
  ----- -------- ------------------ ------------ ---------------------------- ------------------------------------------------------------------------ ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------- ----------------------
  20    Female   Buttock            16 cm        Yes                          None                                                                     Resection                                   No effect of cytotoxic chemotherapy just following the surgery Start of oral and topical paste of Chinese herb four years following the surgery Regression of the lung tumors 6 years after the surgery Progression of the tumor following interruption of the treatment eight years following the surgery   Succumbed to disease (10 years)                                ([@b18-ol-0-0-5696])
  14    Female   Retroperi-toneum   Unknown      None                         Radiotherapy (50 Gy) Embolization                                        Total resection                             Detection of lung metastasis two years following the surgery Soft tissue metastasis and multiple lung metastasis six years following the surgery Diminishing the lung metastasis seven years following the surgery                                                                                           Alive without disease (15 years; personal communication)       ([@b25-ol-0-0-5696])
  14    Male     Thigh              4 cm         None                         Hyperthermia Radiotherapy (30 Gy) Chemotherapy (Cisplatin Pirarubicin)   Wide resection Progression of the disease   Detection of lung metastases four months following the surgery following chemotherapy (Ifosfamide) Decreasing in size and number of metastases following three years                                                                                                                                         Alive without disease (21 years; personal communication)       ([@b26-ol-0-0-5696])
  12    Male     Thigh              Unknown      Yes                          None                                                                     Wide resection                              Regression of multiple lung metastases seven years following the surgery                                                                                                                                                                                                                                     Alive without disease (12 years) (personal communication)      ([@b19-ol-0-0-5696])
  38    Female   Abdominal cavity   16 cm        None                         None                                                                     Biopsy only                                 Detection of lung metastases seven months following the biopsy Disappearance of lung metastases 12 months following the biopsy Brain metastases 14 months after the biopsy                                                                                                                                   Succumbed to disease (20 months)                               ([@b17-ol-0-0-5696])
  12    Male     Thigh              5.5 cm       Yes                          None                                                                     Wide resection                              Autologous lymphocyte infusion (11 cycles for one year) Diminishing the number of the lung metastases Metastatestomy for one lung tumor nine years following initial treatment                                                                                                                               Alive without disease (11 years following initial treatment)   The present study
